Immune-mediated Inflammatory Diseases (IMIDs) and Biologic Therapy: a Medical Revolution

Overview

Journal Postgrad Med J

Publisher Oxford University Press

Specialty General Medicine

Date 2007 Apr 4

PMID 17403952

Citations 115

Authors

Annabel Kuek

Brian L Hazleman

Andrew J K Ostor

Affiliations

Soon will be listed here.

Abstract

Targeted biologic therapies have revolutionised treatment of immune-mediated inflammatory diseases (IMIDs) due to their efficacy, speed of onset and tolerability. The discovery that clinically unrelated conditions, such as rheumatoid arthritis and Crohn's disease, share similar immune dysregulation has led to a shift in the management of IMIDs from one of organ-based symptom relief to mechanism-based treatment. The fact that anticytokine therapy has been effective in treating multiple orphan inflammatory conditions confirms the IMID paradigm. In this review we examine the biologic agents currently licensed for use in the US and Europe: infliximab, etanercept, adalimumab, rituximab, abatacept, anakinra, alefacept and efalizumab. We also discuss the rationale behind the management of IMIDs using rheumatoid arthritis, Crohn's disease, psoriasis and psoriatic arthritis as examples. For the medical profession, IMID represents a breakthrough in the way pathology is classified. In this burgeoning era of biologic therapy the prospect of complete disease remission is conceivable.

Citing Articles

Competencies of nurses to participate in safe medication management practices for biologics: A scoping review.

Li W, Li L, Li L, Xiaodong C, Chen M, Liu H PLoS One. 2025; 20(1):e0317750.

PMID: 39869631 PMC: 11771892. DOI: 10.1371/journal.pone.0317750.

Intestinal Permeability In Subjects With Rheumatoid Arthritis: A Critical Therapeutic Priority.

Guilliams T, Weintraub J, Spar M Integr Med (Encinitas). 2024; 23(5):16-26.

PMID: 39534664 PMC: 11552960.

Risk Factors for the Development of and Outcomes After Diagnosis of Autoimmune Alopecia Areata in Patients with Inflammatory Bowel Diseases.

Pan Y, Lilly E, Ananthakrishnan A Dig Dis Sci. 2024; 69(9):3375-3381.

PMID: 39078458 DOI: 10.1007/s10620-024-08575-7.

Identification of shared disease marker genes and underlying mechanisms between rheumatoid arthritis and Crohn disease through bioinformatics analysis.

Peng P, Shen Y Medicine (Baltimore). 2024; 103(26):e38690.

PMID: 38941374 PMC: 11466148. DOI: 10.1097/MD.0000000000038690.

Impact of a Patient Support Program on time to discontinuation of adalimumab in Australian adult patients with immune-mediated inflammatory diseases-an observational study.

Jones G, Calao M, Begun J, Sin S, Kouhkamari M, Young E PLoS One. 2024; 19(6):e0300624.

PMID: 38870244 PMC: 11175455. DOI: 10.1371/journal.pone.0300624.

References

Gudjonsson J, Johnston A, Sigmundsdottir H, Valdimarsson H . Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol. 2003; 135(1):1-8. PMC: 1808928. DOI: 10.1111/j.1365-2249.2004.02310.x. View

Gregersen P, Silver J, Winchester R . The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987; 30(11):1205-13. DOI: 10.1002/art.1780301102. View

Geboes K, Rutgeerts P, Opdenakker G, Olson A, Patel K, Wagner C . Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin. 2005; 21(11):1741-54. DOI: 10.1185/030079905x65457. View

Lucey D, Clerici M, Shearer G . Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev. 1996; 9(4):532-62. PMC: 172909. DOI: 10.1128/CMR.9.4.532. View

Alamanos Y, Drosos A . Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005; 4(3):130-6. DOI: 10.1016/j.autrev.2004.09.002. View

Krueger G, Ellis C . Psoriasis--recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol. 2005; 53(1 Suppl 1):S94-100. DOI: 10.1016/j.jaad.2005.04.035. View

van den Brande J, Braat H, van den Brink G, Versteeg H, Bauer C, Hoedemaeker I . Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003; 124(7):1774-85. DOI: 10.1016/s0016-5085(03)00382-2. View

Bodger K . Cost of illness of Crohn's disease. Pharmacoeconomics. 2002; 20(10):639-52. DOI: 10.2165/00019053-200220100-00001. View

Gribben J, Freeman G, Boussiotis V, Rennert P, Jellis C, Greenfield E . CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci U S A. 1995; 92(3):811-5. PMC: 42710. DOI: 10.1073/pnas.92.3.811. View

10.

Bathon J, Martin R, Fleischmann R, Tesser J, Schiff M, Keystone E . A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000; 343(22):1586-93. DOI: 10.1056/NEJM200011303432201. View

11.

Kavanaugh A, Antoni C, Krueger G, Yan S, Bala M, Dooley L . Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis. 2005; 65(4):471-7. PMC: 1798094. DOI: 10.1136/ard.2005.040196. View

12.

van de Putte L, Atkins C, Malaise M, Sany J, Russell A, Van Riel P . Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004; 63(5):508-16. PMC: 1755008. DOI: 10.1136/ard.2003.013052. View

13.

Gordon K, Papp K, Hamilton T, Walicke P, Dummer W, Li N . Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003; 290(23):3073-80. DOI: 10.1001/jama.290.23.3073. View

14.

Shanahan F . Crohn's disease. Lancet. 2002; 359(9300):62-9. DOI: 10.1016/S0140-6736(02)07284-7. View

15.

Mease P, Gladman D, Ritchlin C, Ruderman E, Steinfeld S, Choy E . Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52(10):3279-89. DOI: 10.1002/art.21306. View

16.

Genovese M, Bathon J, Fleischmann R, Moreland L, Martin R, Whitmore J . Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol. 2005; 32(7):1232-42. View

17.

Antoni C, Krueger G, de Vlam K, Birbara C, Beutler A, Guzzo C . Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005; 64(8):1150-7. PMC: 1755609. DOI: 10.1136/ard.2004.032268. View

18.

Cooper N . Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2000; 39(1):28-33. DOI: 10.1093/rheumatology/39.1.28. View

19.

Youinou P, Hillion S, Jamin C, Pers J, Saraux A, Renaudineau Y . B lymphocytes on the front line of autoimmunity. Autoimmun Rev. 2006; 5(3):215-21. DOI: 10.1016/j.autrev.2005.06.011. View

20.

Mease P, Kivitz A, Burch F, Siegel E, Cohen S, Ory P . Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004; 50(7):2264-72. DOI: 10.1002/art.20335. View